Mylan has been accused of underpaying Medicaid in rebates for EpiPens, and agreed to pay $465 million to the government to resolve such claims. » Read More
Shopping around for better coverage can cut your monthly premiums and out-of-pocket expenses by hundreds of dollars next year.
Canadian drugmaker Valeant Pharmaceuticals said Friday it will increase the list prices of products in some of its portfolios by 2 percent to 9 percent.
Federal health officials are looking to get more uninsured and younger adults to sign up for Obamacare.
Dr. Peter Bach, Memorial Sloan Kettering physician, discusses how copay assistance programs are actually causing drug prices to rise.
CNBC's Meg Tirrell discusses implications surrounding co-pay assistance programs.
CNBC's Bertha Coombs reports the latest troubles in health care, including why shares of Humana are sinking.
Medicare ratings cuts at Humana may signal a higher bar for other Medicare insurers, an analyst says.
A new study finds the average woman will spend 70 percent of her benefit payouts on medical expenses.
Federal health officials and the drug company Mylan are refusing to explain why full rebates for EpiPen are being delayed.
Zocdoc wants to make "Unsick Days" common, so workers can get checkups during a paid day off without having to worry about repercussions.
Mylan has been under fire for months over sky-high price hikes of anti-allergy EpiPen devices.
After being largely ignored during the first presidential debate, the Affordable Care Act just got a lot of attention from Clinton and Trump.
At the second presidential debate, Republican candidate Donald Trump and Democratic candidate Hillary Clinton clash over their views on the Affordable Care Act.
At the second presidential debate, Democratic candidate Donald Trump answers questions on the Affordable Care Act. Republican Donald Trump defends his position that "Obamacare is a disaster."
It's not clear when EpiPen owner Mylan was told by health officials it was misclassifying the anti-allergy device for rebate purposes.
Mylan's share of revenue from EpiPen due to Medicare and Medicaid more than doubled from 2011-2015.
Get the best of CNBC in your inbox